Skip to content

Cancer Health Center

Font Size

Treatment for Newly Diagnosed Childhood ALL

    Standard Treatment Options for Newly Diagnosed ALL

    Standard treatment options for newly diagnosed childhood acute lymphoblastic leukemia (ALL) include the following:

    Recommended Related to Cancer

    General Information About Gastrointestinal Stromal Tumors Treatment

    Epidemiology Although they comprise fewer than 1% of all gastrointestinal (GI) tumors, gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the GI tract.[1] It has been estimated that there are 3,300 to 6,000 new GIST cases per year in the United States.[2] A study based on Surveillance, Epidemiology and End Results (SEER) registry data found that the age-adjusted yearly incidence of GIST in the United States was 6.8 per million from 1992 to 2000.[3] However, the...

    Read the General Information About Gastrointestinal Stromal Tumors Treatment article > >

    1. Chemotherapy.

    Remission induction therapy

    Induction chemotherapy consists of the following drugs, with or without an anthracycline:

    The Children's Oncology Group (COG) protocols do not administer anthracycline during induction to patients with National Cancer Institute standard-risk precursor B-cell ALL. This three-drug induction regimen results in a complete remission rate of greater than 95% for standard-risk patients.[1]

    Patients treated by other study groups receive a four-drug induction regimen regardless of presenting features:

    • Berlin-Frankfurt-Münster Group in Europe.[2]
    • St. Jude Children's Research Hospital.[3]
    • Dana-Farber Cancer Institute ALL Consortium.[4]

    The most common four-drug induction regimen is vincristine, corticosteroid (either dexamethasone or prednisone), L-asparaginase, and either doxorubicin or daunorubicin. Some studies have suggested that this more intensive induction regimen may result in improved event-free survival (EFS) in patients presenting with high-risk features.[5,6] The COG reserves the use of a four-drug induction for patients with high-risk B-precursor ALL and T-cell ALL.

    For patients who are at standard risk or low risk of treatment failure, four-drug or more induction therapy does not appear necessary for favorable outcome provided that adequate postremission intensification therapy is administered.[5,7,8]

    Corticosteroid therapy

    Many current regimens utilize dexamethasone instead of prednisone during remission induction and later phases of therapy.

    Evidence (dexamethasone):

    1. The Children's Cancer Group conducted a randomized trial comparing dexamethasone and prednisone in standard-risk ALL patients.
      • The trial reported that dexamethasone was associated with a superior EFS.[9]
    2. Another randomized trial was conducted by the United Kingdom Medical Research Council.[10]
      • The trial demonstrated that dexamethasone was associated with a more favorable outcome than prednisolone in all patient subgroups.
      • Patients who received dexamethasone had a significantly lower incidence of both central nervous system (CNS) and non-CNS relapses than patients who received prednisolone.[10]
    3. Other randomized trials did not confirm an EFS advantage with dexamethasone.[11,12]

    The ratio of dexamethasone to prednisone dose used may influence outcome. Studies in which the dexamethasone to prednisone ratio is 1:5 to 1:7 have shown a better result for dexamethasone, while studies using a 1:10 ratio have shown similar outcomes.[13]


      Today on WebMD

      Colorectal cancer cells
      A common one in both men and women.
      Lung cancer xray
      See it in pictures, plus read the facts.
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
      Jennifer Goodman Linn self-portrait
      what is your cancer risk
      colorectal cancer treatment advances
      breast cancer overview slideshow
      prostate cancer overview
      lung cancer overview slideshow
      ovarian cancer overview slideshow
      Actor Michael Douglas